The tumor ablation market was valued at USD 2.17 Billion in 2025. It is poised to grow at a CAGR of 14.20% during the forecast period of 2026-2035, and reach USD 8.19 Billion by 2035. The market growth is driven by a shift toward minimally invasive treatments and a rising global incidence of cancer.
Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for tumor ablation conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.
Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for tumor ablation indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.
Other key players in the market are EDP TMS, Mermaid Medical, CONMED Corporation, Sonablate Corporation, Integra Life Science Holding Corporation, Olympus Corporation, Smith & Nephew PLC.
Latest News on the Tumor Ablation Market (2026)
April 2026: New Modeling Advances Personalized Microwave Ablation for Large Tumors
According to MDPI Bioengineering, a peer-reviewed study published April 2, 2026, introduced a personalized simulation model for overlapping microwave ablation, enabling more precise treatment planning for large solid tumors. The advance is expected to expand microwave ablation use across liver, lung, and kidney oncology and accelerate clinical adoption of conformal ablation strategies.March 2026: Pulsed Field Ablation Expands Into Tumor Treatment Pipelines
According to Cleveland Clinic, ongoing trials are extending nonthermal pulsed field ablation beyond cardiac arrhythmias toward soft-tissue tumor applications, supported by improved tissue selectivity and reduced collateral damage. Growing investigator interest signals new growth opportunities for the tumor ablation market across oncology indications previously dominated by radiofrequency systems.Q1 2026 Market Updates
Geopolitical Impact of Iran, US, and Israel War on the Tumor Ablation Market
United States: The Tumor Ablation Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for tumor ablation conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.
Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for tumor ablation indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.
Key Market Trends and Insights
- By technology, radiofrequency ablation held approximately 33% market share in the historical period.
- By type, percutaneous ablation led the market in the historical period.
- By application, liver cancer held a significant share in the market in the historical period.
Market Size and Forecast
- Market Size (2025): USD 2.17 Billion
- Projected Market Size (2035): USD 8.19 Billion
- CAGR (2026-2035): 14.20%
Tumor Ablation Market Overview
Tumor ablation is a minimally invasive medical procedure used to destroy cancerous or benign tumors in situ without surgical removal. Instead of cutting out the diseased tissue, tumor ablation uses specialized probes to deliver extreme heat, cold, or chemical agents directly to the tumor, causing immediate cell death (necrosis). The market was valued at USD 2.17 Billion in 2025. The market is witnessing a shift toward minimally invasive (MI) therapies and the increasing global burden of cancer.Tumor Ablation Market Growth Drivers
Rising Global Prevalence of Cancer to Accelerate the Market Value
The increasing global burden of cancer is a pivotal catalyst for the tumor ablation sector. According to the World Health Organization, more than 35 million new cancer cases are expected in 2050, driven by aging populations, lifestyle changes, and environmental risk factors. This sharp rise in incidence is significantly increasing the demand for effective, minimally invasive treatment options such as tumor ablation, particularly for liver, lung, kidney, and prostate cancers.Tumor Ablation Market Trends
Some of the notable trends in the market are technological advancements and modalities, integration with advanced imaging, and multimodal and combination therapies:
Growing Pulsed Electric Field Ablation Advancements are Likely to Enhance the Market Growth
The growing adoption of pulsed electric field (PEF) ablation is emerging as a transformative trend in tumor ablation, driven by its ability to achieve precise, non-thermal tumor destruction while preserving surrounding tissues. In November 2025, Galvanize Therapeutics reported positive clinical findings demonstrating strong local tumor control and potential immune response activation using its Aliya PEF technology in lung cancer patients. This advancement highlights the increasing integration of innovative ablation modalities, supporting improved treatment outcomes and driving sustained market growth.Tumor Ablation Market Segmentation
Market Breakup by Technology
- Radiofrequency Ablation
- Microwave Ablation
- Cryoablation
- HIFU
- Others
Market Breakup by Type
- Surgical Ablation
- Percutaneous Ablation
- Laparoscopic Ablation
Market Breakup by Application
- Kidney Cancer
- Liver Cancer
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Bone Cancer
Market Breakup by End User
- Hospitals
- Oncology Centers
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Tumor Ablation Market Share
Radiofrequency Ablation (RFA) Market Segmentation by Type
Radiofrequency ablation (RFA) is expected to hold a significant share in the market due to its extensive clinical track record and high safety profile compared to newer thermal modalities. RFA is now a complementary gold-standard tool in oncology, providing effective targeted destruction for liver, lung, and kidney tumors with minimal collateral damage. Recent financial economics suggest that, despite high initial equipment costs, RFA's curative nature reduces long-term healthcare resource consumption by minimizing repeat ER visits and chronic medication needs.Tumor Ablation Market Analysis by Region
The regions included in the market are North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is likely to hold a substantial share in the market, driven by advanced healthcare infrastructure, high adoption of minimally invasive technologies, and strong investment in oncology research. The presence of major market players and favorable reimbursement frameworks further supports regional dominance. Additionally, increasing integration of AI diagnostics, molecular profiling, and biomarker-based treatment enhances clinical outcomes, reinforcing North America’s position as the primary contributor to global market growth.Leading Players in the Tumor Ablation Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic PLC
Medtronic is a global powerhouse in both cardiac and surgical ablation. In late 2024, it secured FDA approval for the Affera Mapping and Ablation System, a versatile platform using the Sphere-9 catheter to deliver both PFA and radiofrequency energy. This follows its earlier PulseSelect PFA launch, maintaining its leadership as EPs shift from cryoablation to more efficient, non-thermal modalities.Boston Scientific Corporation
Boston Scientific is a major player in the market, with its FARAPULSE system. The company’s growth is driven by the FARAWAVE NAV catheter, which integrates mapping and therapy to reduce device swaps. Beyond cardiology, the acquisition of Relievant Medsystems adds the Intracept system for specialized intraosseous nerve ablation in chronic pain.Johnson & Johnson
Johnson & Johnson maintains a massive electrophysiology footprint through its Biosense Webster subsidiary. Its flagship VARIPULSE Platform is the first PFA system fully integrated with the CARTO 3 mapping system, emphasizing procedural accuracy and safety. The company is also advancing dual-energy solutions, like the THERMOCOOL SMARTTOUCH SF catheter, which allows toggling between RF and PF energy.AngioDynamics
AngioDynamics has pivoted away from traditional radiofrequency to focus on high-growth "MedTech" segments like oncology. Its standout platform is NanoKnife, which utilizes Irreversible Electroporation (IRE) for soft tissue ablation, including prostate tissue. By divesting its legacy RF business, the company has sharpened its focus on non-thermal, image-guided therapeutics for cancer and vascular health.Other key players in the market are EDP TMS, Mermaid Medical, CONMED Corporation, Sonablate Corporation, Integra Life Science Holding Corporation, Olympus Corporation, Smith & Nephew PLC.
Key Questions Answered in the Tumor Ablation Market Report
- What was the tumor ablation market value in 2025?
- What is the tumor ablation market forecast outlook for 2026-2035?
- What major factors aid the demand for the tumor ablation market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major tumor ablation market trends?
- Which technology is expected to dominate the market segment?
- Which type is projected to lead the market segment?
- Which application is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players in the tumor ablation market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
1 Preface
3 Global Tumor Ablation Market Overview
4 Global Tumor Ablation Market Landscape*
5 Global Tumor Ablation Market Dynamics
6 Global Tumor Ablation Market Segmentation (219-2035)
7 North America Tumor Ablation Market (219-2035)
8 Europe Tumor Ablation Market (219-2035)
9 Asia Pacific Tumor Ablation Market (219-2035)
10 Latin America Tumor Ablation Market (219-2035)
11 Middle East and Africa Tumor Ablation Market (219-2035)
12 Regulatory Framework
13 Patent Analysis
14 Grants Analysis
15 Funding and Investment Analysis
16 Partnership and Collaborations Analysis
17 Supplier Landscape
Companies Mentioned
- Medtronic PLC
- Boston Scientific Corporation
- Johnson & Johnson
- AngioDynamics
